AbbVie Inc. (ABBV) Yield on Cost (YOC): 2.98%
The yield on cost (YOC) for AbbVie Inc. (ABBV) is 2.98%.
ABBV Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
2.98%
Forward Yield on Cost Projections
If you buy ABBV today at the current stock price of $225.96 with a yield of 2.98% and dividends continue to grow at the historical rate (6.8% CAGR), your YOC would be:
Current Yield
2.98%
YOC in 3 Years
3.76%
YOC in 5 Years
4.39%
YOC in 10 Years
6.47%
Interactive Yield on Cost Calculator
Project custom investment returns for AbbVie Inc. (ABBV) based on your custom cost basis.
Starting Yield
2.98%
Ending YOC
8.01%
Year 15 Dividend
$18.11
Cum. Dividends Recd.
$178.28
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $6.74 | — | 2.98% | $0.00 |
| Year 1 | $7.20 | +6.81% | 3.19% | $7.20 |
| Year 2 | $7.69 | +6.81% | 3.40% | $14.89 |
| Year 3 | $8.21 | +6.81% | 3.63% | $23.10 |
| Year 4 | $8.77 | +6.81% | 3.88% | $31.87 |
| Year 5 | $9.37 | +6.81% | 4.15% | $41.24 |
| Year 6 | $10.01 | +6.81% | 4.43% | $51.25 |
| Year 7 | $10.69 | +6.81% | 4.73% | $61.94 |
| Year 8 | $11.42 | +6.81% | 5.05% | $73.36 |
| Year 9 | $12.19 | +6.81% | 5.40% | $85.55 |
| Year 10 | $13.03 | +6.81% | 5.76% | $98.58 |
| Year 11 | $13.91 | +6.81% | 6.16% | $112.49 |
| Year 12 | $14.86 | +6.81% | 6.58% | $127.35 |
| Year 13 | $15.87 | +6.81% | 7.02% | $143.22 |
| Year 14 | $16.95 | +6.81% | 7.50% | $160.17 |
| Year 15 | $18.11 | +6.81% | 8.01% | $178.28 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
AbbVie Inc. Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for AbbVie Inc. (ABBV)?
- The yield on cost (YOC) for ABBV stock is 2.98%.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael